Development of PRS-400, an inhaled Jagged-1 Anticalin protein for the treatment of muco-obstructive lung diseases

M. Hagner (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), J. Peper-Gabriel (Hallbergmoos, Germany), D. Jaquin (Hallbergmoos, Germany), N. Quilitz (Hallbergmoos, Germany), C. Hechinger (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), K. Heinig (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), S. Grüner (Hallbergmoos, Germany), J. Prassler (Hallbergmoos, Germany), R. Bel Aiba (Hallbergmoos, Germany), J. Mayer (Hallbergmoos, Germany), R. Bharti (Hallbergmoos, Germany), J. Wrennall (Chapel Hill, United States), R. Tarran (Chapel Hill, United States), A. Ray (Pittsburgh, United States), S. Wenzel (Pittsburgh, United States), C. Rothe (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany), G. Matschiner (Hallbergmoos, Germany), A. Fysikopoulos (Hallbergmoos, Germany)

Source: International Congress 2022 – Emerging therapeutic targets, biomarkers and mechanisms of chronic lung disease

Session: Emerging therapeutic targets, biomarkers and mechanisms of chronic lung disease
Session type: Thematic Poster
Number: 3568

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Hagner (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), J. Peper-Gabriel (Hallbergmoos, Germany), D. Jaquin (Hallbergmoos, Germany), N. Quilitz (Hallbergmoos, Germany), C. Hechinger (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), K. Heinig (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), S. Grüner (Hallbergmoos, Germany), J. Prassler (Hallbergmoos, Germany), R. Bel Aiba (Hallbergmoos, Germany), J. Mayer (Hallbergmoos, Germany), R. Bharti (Hallbergmoos, Germany), J. Wrennall (Chapel Hill, United States), R. Tarran (Chapel Hill, United States), A. Ray (Pittsburgh, United States), S. Wenzel (Pittsburgh, United States), C. Rothe (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany), G. Matschiner (Hallbergmoos, Germany), A. Fysikopoulos (Hallbergmoos, Germany). Development of PRS-400, an inhaled Jagged-1 Anticalin protein for the treatment of muco-obstructive lung diseases. 3568

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.